Adlai Nortye (NASDAQ:ANL) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Adlai Nortye (NASDAQ:ANL) in a report released on Friday, MarketBeat.com reports. The firm currently has a $9.00 price objective on the stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a report on Thursday, June 20th.

Adlai Nortye Stock Performance

Adlai Nortye stock opened at $1.95 on Friday. Adlai Nortye has a 12 month low of $1.85 and a 12 month high of $17.48. The business’s 50 day simple moving average is $2.39 and its 200 day simple moving average is $5.66.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.